semaglutide canada patent expiry (Ozempic) Market: Navigating The Cliff And Strategic Implications Novo Nordisk to lose blockbuster

That finding stands on its own and it does not need the mechanism to be overstated to be impressive

How might this impact on clinical practice in the foreseeable future

Patients with type 2 diabetes and dyslipidaemia represent the most appropriate group for GLP-1 therapy when glycaemic targets are not achieved with other treatments

Later trials that combined tirzepatide with a structured lifestyle programme, such as SURMOUNT-3, found even greater results, with participants achieving an additional 18.4% mean weight reduction from randomization to week 72 on top of initial lifestyle-driven losses

Yanai, H., Adachi, H., Hamasaki, H., Masui, Y., et